JP2008539794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008539794A5 JP2008539794A5 JP2008512536A JP2008512536A JP2008539794A5 JP 2008539794 A5 JP2008539794 A5 JP 2008539794A5 JP 2008512536 A JP2008512536 A JP 2008512536A JP 2008512536 A JP2008512536 A JP 2008512536A JP 2008539794 A5 JP2008539794 A5 JP 2008539794A5
- Authority
- JP
- Japan
- Prior art keywords
- biological sample
- level
- therapeutic agent
- biomarker
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150013553 CD40 gene Proteins 0.000 claims 73
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 73
- 239000012472 biological sample Substances 0.000 claims 73
- 238000000034 method Methods 0.000 claims 67
- 239000000090 biomarker Substances 0.000 claims 47
- 239000003814 drug Substances 0.000 claims 44
- 229940124597 therapeutic agent Drugs 0.000 claims 44
- 108010029697 CD40 Ligand Proteins 0.000 claims 30
- 102100032937 CD40 ligand Human genes 0.000 claims 30
- 210000004027 cell Anatomy 0.000 claims 25
- 239000000523 sample Substances 0.000 claims 21
- 210000005170 neoplastic cell Anatomy 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 238000012360 testing method Methods 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 14
- 230000019491 signal transduction Effects 0.000 claims 14
- 208000006994 Precancerous Conditions Diseases 0.000 claims 9
- 230000001404 mediated effect Effects 0.000 claims 9
- 230000006907 apoptotic process Effects 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 8
- 239000008280 blood Substances 0.000 claims 8
- 239000012503 blood component Substances 0.000 claims 8
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims 7
- 230000004083 survival effect Effects 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000003550 marker Substances 0.000 claims 6
- 208000003950 B-cell lymphoma Diseases 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 230000027455 binding Effects 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 229950004563 lucatumumab Drugs 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 108010063916 CD40 Antigens Proteins 0.000 claims 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 102000043136 MAP kinase family Human genes 0.000 claims 3
- 108091054455 MAP kinase family Proteins 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 230000008901 benefit Effects 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 230000009467 reduction Effects 0.000 claims 3
- 108091007065 BIRCs Proteins 0.000 claims 2
- 102000051485 Bcl-2 family Human genes 0.000 claims 2
- 108700038897 Bcl-2 family Proteins 0.000 claims 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 2
- 102000011727 Caspases Human genes 0.000 claims 2
- 108010076667 Caspases Proteins 0.000 claims 2
- 102000000018 Chemokine CCL2 Human genes 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 102100033078 TNF receptor-associated factor 1 Human genes 0.000 claims 2
- 108090000920 TNF receptor-associated factor 1 Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000008859 change Effects 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 230000003325 follicular Effects 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 238000013467 fragmentation Methods 0.000 claims 2
- 238000006062 fragmentation reaction Methods 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000011002 quantification Methods 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 230000007730 Akt signaling Effects 0.000 claims 1
- 102000004121 Annexin A5 Human genes 0.000 claims 1
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 claims 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 claims 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims 1
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 108090000397 Caspase 3 Proteins 0.000 claims 1
- 108090000567 Caspase 7 Proteins 0.000 claims 1
- 102100029855 Caspase-3 Human genes 0.000 claims 1
- 102100038902 Caspase-7 Human genes 0.000 claims 1
- 102100026550 Caspase-9 Human genes 0.000 claims 1
- 108090000566 Caspase-9 Proteins 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000011767 Sarcoma of cervix uteri Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 102000050257 X-Linked Inhibitor of Apoptosis Human genes 0.000 claims 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 claims 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 239000000158 apoptosis inhibitor Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 208000014514 chromosome 17p deletion Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 208000021173 high grade B-cell lymphoma Diseases 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 108091006086 inhibitor proteins Proteins 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 238000007899 nucleic acid hybridization Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 238000013042 tunel staining Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68258205P | 2005-05-18 | 2005-05-18 | |
| US60/682,582 | 2005-05-18 | ||
| US74928505P | 2005-12-09 | 2005-12-09 | |
| US60/749,285 | 2005-12-09 | ||
| PCT/US2006/019414 WO2006125143A2 (en) | 2005-05-18 | 2006-05-18 | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012272271A Division JP2013057686A (ja) | 2005-05-18 | 2012-12-13 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008539794A JP2008539794A (ja) | 2008-11-20 |
| JP2008539794A5 true JP2008539794A5 (enExample) | 2009-09-24 |
| JP5208730B2 JP5208730B2 (ja) | 2013-06-12 |
Family
ID=37022828
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512536A Expired - Fee Related JP5208730B2 (ja) | 2005-05-18 | 2006-05-18 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
| JP2012272271A Pending JP2013057686A (ja) | 2005-05-18 | 2012-12-13 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012272271A Pending JP2013057686A (ja) | 2005-05-18 | 2012-12-13 | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8337851B2 (enExample) |
| EP (1) | EP1894012A2 (enExample) |
| JP (2) | JP5208730B2 (enExample) |
| AU (1) | AU2006247067B2 (enExample) |
| CA (1) | CA2608751A1 (enExample) |
| WO (1) | WO2006125143A2 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8337851B2 (en) * | 2005-05-18 | 2012-12-25 | Novartis Ag | Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer |
| US9005974B2 (en) | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| HUE037580T2 (hu) | 2005-12-09 | 2018-09-28 | Academisch Medisch Centrum Bij De Univ Van Amsterdam | Eszközök és eljárások ellenanyag-termelõ sejtek stabilitásának befolyásolására |
| US20090075272A1 (en) * | 2006-01-20 | 2009-03-19 | Hollmann C Annette | Method to Identify CD40-Sensitive Cells Using Gene Expression |
| US8945564B2 (en) | 2006-04-21 | 2015-02-03 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
| DE602006004196D1 (de) * | 2006-06-01 | 2009-01-22 | Cellzome Ag | Verfahren zur Identifizierung von mit ZAP-70 wechselwirkenden Molekülen und zur ZAP-70-Reinigung |
| US9068230B2 (en) | 2007-11-07 | 2015-06-30 | Genentech, Inc. | Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
| ES2605228T3 (es) * | 2009-04-18 | 2017-03-13 | Genentech, Inc. | Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40 |
| US9085798B2 (en) | 2009-04-30 | 2015-07-21 | Prognosys Biosciences, Inc. | Nucleic acid constructs and methods of use |
| AU2010271583B2 (en) | 2009-07-15 | 2015-02-12 | Kling Biotherapeutics B.V. | Means and methods for producing high affinity antibodies |
| US20110064747A1 (en) * | 2009-08-25 | 2011-03-17 | Rangaprasad Sarangarajan | Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10) |
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| US9371598B2 (en) | 2010-04-05 | 2016-06-21 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
| AU2011242990B2 (en) * | 2010-04-19 | 2015-02-12 | Biomarker Strategies, Llc. | Compositions and methods for prediction of drug sensitivity, resistance, and disease progression |
| WO2012075111A1 (en) | 2010-11-30 | 2012-06-07 | Novartis Ag | Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers |
| US9206247B2 (en) * | 2010-12-02 | 2015-12-08 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| EP3150750B1 (en) | 2011-04-08 | 2018-12-26 | Prognosys Biosciences, Inc. | Peptide constructs and assay systems |
| GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
| MX339239B (es) | 2011-04-29 | 2016-05-18 | Apexigen Inc | Anticuerpos anti-cd40 y metodos de uso. |
| USRE50065E1 (en) | 2012-10-17 | 2024-07-30 | 10X Genomics Sweden Ab | Methods and product for optimising localised or spatial detection of gene expression in a tissue sample |
| AU2013337903B2 (en) | 2012-10-30 | 2018-08-16 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| CN105358984B (zh) | 2013-03-15 | 2020-02-18 | 普罗格诺西斯生物科学公司 | 用于检测肽/mhc/tcr结合的方法 |
| CN111500680B (zh) | 2013-06-25 | 2024-04-16 | 普罗格诺西斯生物科学公司 | 检测样品中生物靶标的空间分布的方法和系统 |
| WO2015070037A2 (en) | 2013-11-08 | 2015-05-14 | Prognosys Biosciences, Inc. | Polynucleotide conjugates and methods for analyte detection |
| WO2015085171A1 (en) * | 2013-12-06 | 2015-06-11 | Adventist Health Systems/Sunbelt, Inc. | Role of mcp-1 in relapse of acute myeloid leukemia after hematopoietic stem cell transplantation |
| EP3099709B1 (en) | 2014-01-31 | 2019-12-25 | AIMM Therapeutics B.V. | Means and methods for producing stable antibodies |
| DK3210142T3 (da) * | 2014-10-24 | 2020-11-16 | Koninklijke Philips Nv | Vurdering af tgf-cellulær signaleringsvejaktivitet under anvendelse af matematisk modellering af målgenekspression |
| US10774374B2 (en) | 2015-04-10 | 2020-09-15 | Spatial Transcriptomics AB and Illumina, Inc. | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
| JP2018523823A (ja) * | 2015-08-04 | 2018-08-23 | セルジーン コーポレイション | 慢性リンパ球性白血病の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの利用 |
| ES2885476T3 (es) * | 2015-10-05 | 2021-12-13 | Ucb Biopharma Sprl | Firmas moleculares para uso en diagnóstico y análisis de respuesta al tratamiento de enfermedades autoinmunes |
| SG11201903557SA (en) * | 2016-10-23 | 2019-05-30 | Berkeley Lights Inc | Methods for screening b cell lymphocytes |
| US20210215697A1 (en) * | 2018-05-14 | 2021-07-15 | Bergenbio Asa | Serum Biomarkers |
| JP2021528393A (ja) | 2018-06-15 | 2021-10-21 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 後細胞シグナル伝達因子の調節による免疫活性の上昇 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| WO2020243579A1 (en) | 2019-05-30 | 2020-12-03 | 10X Genomics, Inc. | Methods of detecting spatial heterogeneity of a biological sample |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
| EP4153775B1 (en) | 2020-05-22 | 2024-07-24 | 10X Genomics, Inc. | Simultaneous spatio-temporal measurement of gene expression and cellular activity |
| CN116249785A (zh) | 2020-06-02 | 2023-06-09 | 10X基因组学有限公司 | 用于抗原-受体的空间转录组学 |
| AU2021283174A1 (en) | 2020-06-02 | 2023-01-05 | 10X Genomics, Inc. | Nucleic acid library methods |
| EP4162074B1 (en) | 2020-06-08 | 2024-04-24 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
| WO2022006179A1 (en) | 2020-06-29 | 2022-01-06 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| CN113684180B (zh) * | 2021-08-31 | 2023-05-26 | 山东大学第二医院 | 一种提高骨髓瘤杀伤活性的nk细胞制备方法 |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| CN115845063B (zh) * | 2022-12-20 | 2024-07-09 | 中国医学科学院医学生物学研究所 | 与急性t淋巴细胞白血病治疗相关的靶点cd40lg及其应用 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024173352A2 (en) * | 2023-02-13 | 2024-08-22 | Shattuck Labs, Inc. | Methods of treating cancer with a sirp1a-based chimeric protein |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1079824T3 (da) * | 1998-05-19 | 2011-11-21 | Res Dev Foundation | Triterpen-sammensætninger og fremgangsmåder til anvendelse deraf |
| CN1437478A (zh) * | 2000-04-25 | 2003-08-20 | Idec药物公司 | 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗 |
| US7288252B2 (en) * | 2000-10-02 | 2007-10-30 | Novartis Vaccines And Diagnostics, Inc. | Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1575574A4 (en) * | 2002-10-30 | 2007-11-07 | Blood Res Center | METHOD FOR TREATING AND PREVENTING APOPTOSIS-BASED DISEASES BY MEANS OF RNA INTERFERENCE AGENTS |
| ES2246191T1 (es) * | 2002-12-11 | 2006-02-16 | Ventana Medical Systems, Inc. | Metodo para predecir la respuesta a la terapia dirigida a her2. |
| GB0301566D0 (en) * | 2003-01-23 | 2003-02-26 | Eirx Therapeutics Ltd | Kinasaes and GPCRs involved in apoptosis |
| JP4810431B2 (ja) * | 2003-11-04 | 2011-11-09 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｂ細胞に関連する癌に対する治療方法 |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| ATE476448T1 (de) * | 2003-11-04 | 2010-08-15 | Novartis Vaccines & Diagnostic | Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung |
| EP1718602A4 (en) * | 2004-01-30 | 2007-12-12 | Peplin Biolipids Pty Ltd | THERAPEUTIC AND CARRIER MOLECULES |
| US20070292439A1 (en) * | 2004-04-27 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use |
| US8337851B2 (en) * | 2005-05-18 | 2012-12-25 | Novartis Ag | Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer |
-
2006
- 2006-05-18 US US11/914,714 patent/US8337851B2/en not_active Expired - Fee Related
- 2006-05-18 CA CA002608751A patent/CA2608751A1/en not_active Abandoned
- 2006-05-18 WO PCT/US2006/019414 patent/WO2006125143A2/en not_active Ceased
- 2006-05-18 JP JP2008512536A patent/JP5208730B2/ja not_active Expired - Fee Related
- 2006-05-18 AU AU2006247067A patent/AU2006247067B2/en not_active Ceased
- 2006-05-18 EP EP06770643A patent/EP1894012A2/en not_active Withdrawn
-
2012
- 2012-12-13 JP JP2012272271A patent/JP2013057686A/ja active Pending
- 2012-12-17 US US13/717,175 patent/US20130230528A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008539794A5 (enExample) | ||
| Bertrand et al. | TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma | |
| Padro et al. | Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia | |
| Rassouli et al. | Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma | |
| Mantovani et al. | Tumour-associated macrophages as treatment targets in oncology | |
| Koornstra et al. | Expression of TRAIL (TNF‐related apoptosis‐inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas | |
| JP2008539791A5 (enExample) | ||
| Moon et al. | Aberrant recruitment and activation of T cells in diabetic nephropathy | |
| JP5409628B2 (ja) | 抗ｔｗｅａｋ受容体抗体の治療上の使用 | |
| Yin et al. | RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response | |
| KR102739338B1 (ko) | 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법 | |
| Lassen et al. | A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers | |
| Devan et al. | Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma | |
| CN112955748A (zh) | 治疗癌症的方法 | |
| WO2012082742A2 (en) | Detecting cancer with anti-ccl25 and anti-ccr9 antibodies | |
| WO2013103637A1 (en) | Analysis and targeting of ror2 in cancer | |
| Ye et al. | Enavatuzumab, a humanized anti‐TWEAK receptor monoclonal antibody, exerts antitumor activity through attracting and activating innate immune effector cells | |
| JP2024511373A (ja) | がんのためのバイオマーカーおよびその使用 | |
| Meulendijks et al. | Exposure and tumor Fn14 expression as determinants of pharmacodynamics of the anti-TWEAK monoclonal antibody RG7212 in patients with Fn14-positive solid tumors | |
| CN112424608A (zh) | 用于疾病的预后和管理的方法 | |
| Bedewy et al. | CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma | |
| Wada et al. | Expression of BAFF‐R and TACI in reactive lymphoid tissues and B‐cell lymphomas | |
| EP2898330B1 (en) | Predicting the sensitivity of a subject to chemotherapy | |
| Chereches et al. | Biomarkers for the early detection of relapses in metastatic colorectal cancers | |
| Rikhof et al. | Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL |